Kura Oncology

140 articles with Kura Oncology

• Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum

  6/11/2020

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology & Oncology Forum (Virtual). Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat on Thursday, June 18, 2020 at 10:40 a.m. ET / 7:40 a.m. PT. The virtual foru

• 

  Clinical Catch-Up: May 25-29

  6/1/2020

  In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.

• Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma

  5/29/2020

  Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC

• Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific Program

  5/13/2020

  Oral presentation to highlight clinical data for tipifarnib in HRAS mutant solid tumors, including overall survival data in head and neck squamous cell carcinoma

• Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares - May 08, 2020

  5/8/2020

  Kura Oncology, Inc. announced the closing of its previously announced underwritten public offering of 10,465,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,365,000 shares, at a public offering price of $13.75 per share.

• Kura Oncology to Present at BofA Securities Virtual Health Care Conference 2020

  5/7/2020

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation at the BofA Securities Virtual Healthcare Conference 2020.

• Kura Oncology Announces Pricing of $125 Million Public Offering of Common Stock

  5/6/2020

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a price to the public of $13.75 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable b

• Kura Oncology Announces Commencement of Public Offering of Common Stock - May 05, 2020

  5/5/2020

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

• Kura Oncology Reports First Quarter 2020 Financial Results

  5/4/2020

  Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML

• Kura Oncology to Report First Quarter 2020 Financial Results

  4/29/2020

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter 2020 financial results after the close of U.S. financial markets on Monday, May 4, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate

• Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas

  3/3/2020

  Kura Oncology, Inc. (Nasdaq: KURA),today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype.

• Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results

  2/25/2020

  Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021

• Kura Oncology to Participate in Three Upcoming Investor Conferences - Feb. 19, 2020

  2/19/2020

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences

• Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results

  2/18/2020

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2019 financial results after the close of U.S. financial markets on Tuesday, February 25, 2020

• Kura Oncology Announces Transition of Chief Medical Officer

  1/23/2020

  Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that Antonio Gualberto, M.D., Ph.D., will step down as Head of Development and Chief Medical Officer to pursue other opportunities.

• Kura Oncology to Present at the 38th Annual J.P. Morgan Healthcare Conference

  1/9/2020

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, announced its participation at the 38th Annual J.P. Morgan Healthcare Conference.

• Kura Oncology Appoints Kirsten Flowers as Chief Commercial OfficerCompany strengthens leadership team to support pre-commercial efforts and launch optimization

  1/6/2020

  Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, announced the appointment of Kirsten Flowers as Chief Commercial Officer.

• Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial

  12/16/2019

  Kura Oncology Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib

• Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

  12/8/2019

  Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma

• Kura Oncology to Participate in Piper Jaffray Healthcare Conference

  11/26/2019

  Kura Oncology, Inc. announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019 at 12:00 p.m. ET / 9:00 a.m. PT.